ArticleExperimental and therapeutic medicine2026
Nasopharyngeal carcinoma with inguinal lymph node metastasis: A case report.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) usually metastasizes to cervical lymph nodes, whereas inguinal lymph node metastases (ILNM) are rare, with only a small number of cases reported. ILNs are an uncommon site of secondary involvement, a phenomenon attributed to their unique anatomical and immunological features. The current study reported a case of NPC in which baseline positron emission tomography/CT showed metastasis from the left pharyngeal recess to the left cervical levels II-III. Mildly increased metabolic activity was observed in levels II-III of the right cervical chain, the left supraclavicular area and the bilateral inguinal area, initially interpreted as reactive hyperplasia. The patient was diagnosed with NPC (T2N1M0, stage IIA, 8th edition of the American Joint Committee on Cancer). At 5 months after the completion of induction chemotherapy and concurrent chemoradiotherapy, the bilateral ILNs showed interval enlargement and biopsy confirmed metastatic NPC. The patient was classified as stage IVB based on biopsy results, prompting appropriate treatment for this advanced stage. This rare case underscores the importance of considering ILNM as a possible metastatic site in NPC, requiring clinicians to perform timely evaluations and lymph node biopsies to prevent clinical understaging due to unrecognized occult metastatic disease, particularly during the early stages of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.